What kind of targeted drug is osimertinib?

Osimertinib (Osimertinib) is a targeted drug targeting specific gene mutations and is a small molecule tyrosine kinase inhibitor. Osimertinib is a third-generation targeted therapy drug that can specifically inhibit sensitive mutations in the epidermal growth factor receptor (EGFR) and resistance mutations in T790M. By binding to specific targets on EGFR, osimertinib can accurately kill tumor cells and reduce damage to normal cells.

Osimertinib has been approved for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) who have sensitive mutations in the EGFR gene. This means that osimertinib can be used as the first-choice treatment for patients who are diagnosed with EGFR gene mutations upon initial diagnosis.

For patients who develop T790M resistance mutations after receiving targeted therapy with first- or second-generation small molecule tyrosine kinase inhibitors, osimertinib also shows good efficacy and can be used as a second-line and later-line targeted therapy option. Osimertinib can also be used as adjuvant treatment for early-stage non-small cell lung cancer after surgery, helping to reduce the risk of recurrence.

Osimertinib is a highly selective EGFR mutant inhibitor, targeting exon19 deletionEGFR, L858R/T790M EGFRand wild-type EGFRhave significant inhibitory effects. Their IC50 values (half inhibitory concentrations) are 12.92 nM, 11.44 nM and 493.8 respectively. nM, showing highly selective inhibition of mutantEGFR.

Before using osimertinib, patients should undergo genetic testing to confirm the presence of sensitive mutations in the EGFR gene. At the same time, doctors will adjust the dosage and regimen according to the patient's specific conditions. It is worth noting that although most of the adverse reactions of osimertinib are mild, such as diarrhea, rash, etc., a few patients may have serious adverse reactions, such as abnormal electrocardiogram, neutropenia, etc. At this time, they need to suspend the medication and seek medical treatment in time.